Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-126-1 | CAS number: 134-03-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
The substance is not carcinogenic. The NOAEL was determined to be 2560 mg/kg bw/day.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 451 (Carcinogenicity Studies)
- Deviations:
- no
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Route of administration:
- oral: feed
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): at least once per week
- Mixing appropriate amounts with: Purina (TM) Lab Chow
- Storage temperature of food: 23°C
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Standards were prepared at the 25,000-and 50,000-ppm levels by weighing appropriate amounts of ascorbic acid into a total of 1 gram of dosed feed. Standards were shaken by hand and vortexed to assure a good mix. Samples and standards were then extracted twice with 50-ml aliquots of deionized water. The combined supernatants were spiked with 1.0 mL of starch solution and titrated with 0.0884 N iodine solution. Each milliliter of the iodine solution is equivalent to 7.779 mg of ascorbic acid. Standards produced an average recovery of 100.8% & 3.8%. Analyses were performed in duplicate, and concentra- tions reported represent values corrected for recovery.
- Duration of treatment / exposure:
- 103 weeks
- Frequency of treatment:
- daily
- Post exposure period:
- none
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- control groups
- Dose / conc.:
- 25 000 mg/kg diet
- Remarks:
- low dose groups
- Dose / conc.:
- 50 000 mg/kg diet
- Remarks:
- high dose groups
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, concurrent no treatment
- Positive control:
- not needed
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: body weights by cage every week during the first 13 weeks, monthly thereafter. Mean bodoy weights were calculated by dividing the weight of teh group by the number of animals of the group.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal group determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY:No
CLINICAL CHEMISTRY: YNo
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Probability of survival (Kaplan and Meier), tumor incidence data (Mantel and Haenszel); test of significance. Fisher's t-test; Cochran-Armitage test for dose-reponse trends
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- Survival of dosed and control female rats and of dosed and control female mice were comparable. Survival of high-dose male rats was slightly greater than that of the controls (P=0.087). Survival of high-dose male mice was significantly greater (P=0.009) than that of the controls.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Throughout most of the study, mean body weights of dosed female rats and dosed female mice were lower than those of the controls. Final body weights were comparable among groups, except for the high-dose female rats (<13%); marginal differences (<8%) were observed for low-dose female rats and for dosed female mice (8%-11%).
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption was equivalent among groups.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Most observational differences were confined to the female rat. The incidence of low-dose female rats with undifferentiated (mononuclear-cell) leukemias (control, 6/50, 12%; low-dose, 17/ 50, 34%; high-dose, 12/50, 24%) was significantly higher (P<0.02) than that in controls. These tumors were not considered to be related to administration of L-ascorbic acid because they did not occur in the female high-dose group at incidences significantly greater (P>0.07) than those in the controls, the trend test was not significant (P10.07), and no increases were observed for male rats.
- Relevance of carcinogenic effects / potential:
- These borderline increases and decreases in neoplastic lesions, as well as the decrease in non-neoplastic effects in female rats, were considered to be insufficient evidence for a compound-related effect.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 2 560 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: no adverse effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 3 050 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: no adverse effects observed
- Key result
- Critical effects observed:
- no
- Conclusions:
- Ascorbic acid was not carcinogenic for male and female rats and male and female mice.
- Executive summary:
A carcinogenesis bioassay of L-ascorbic acid (>97%pure) was conducted by administering diets containing 25,000 or 50,000 ppm ascorbic acid to groups of 50 F344/N rats of each sex for 103 weeks. Controls consisted of 50 untreated rats of each sex. Fifty-thousand ppm is the highest dose recommended for chronic studies.
Survival of dosed and control female rats were comparable. Survival of high-dose male rats was slightly greater than that of the controls (P=0.087). Throughout most of the study, mean body weights of dosed female rats were lower than those of the controls. Final body weights were comparable among groups, except for the high-dose female rats (<13%); marginal differences (<8%) were observed for low-dose female rats. Food consumption was equivalent among groups. Most observational differences were confined to the female rat. The incidence of low-dose female rats with undifferentiated (mononuclear-cell) leukaemias (control, 6/50, 12%; low-dose,17/ 50, 34%; high-dose,12/50, 24%) was significantly higher (P<0.02) than that in controls. These tumours were not considered to be related to administration of L-ascorbic acid because they did not occur in the female high-dose group at incidences significantly greater (P>0.07) than those in the controls, the trend test was not significant (P10.07), and no increases were observed for male rats. Under the conditions of this bioassay, ascorbic acid was not carcinogenic for male and female F344/N rats. The NOAEL values are 2,560 mg/kg bw and day for male rats, and 3,050 mg/kg bw and day for female rats in this study, derived from the calculated mean dose of the high dose groups (NTP, 1983).
Additionally, a second carcinogenicity oral feed study with ascorbic acid at 25,000 and 50,000 ppm in the diet using male and female B6C3F1 mice was also conducted. The results were comparable (not described in detail in this dossier). Most notably, ascorbic acid was not carcinogenic for male and female mice. The NOAEL values are 12,788 mg/kg bw and day for male and 14,792 mg/kg bw and day for female mice, derived from the calculated mean dose of the high dose groups (NTP, 1983).
Both studies are considered to be valid and suitable for assessment of the endpoints repeated dose toxicity (see also the preceding rat and mouse 90-day studies) and genotoxicity.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 2 560 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- The quality of the data base is excellent as two fully valid ascorbic acid oral feed carcinogenicity studies in two species (rat and imouse) are available.
The result can be adopted for sodium ascorbate as this is the coresponding base to ascorbic acid. A detailed justification for read across has been provided.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. The data did not indicate carcinogenic properties of the test substance. Based on available data on carcinogenicity, the test item is not classified according to Regulation (EC) No 1272/2008 (CLP), as amended for the tenth time in Regulation (EU) No 2017/776.
Additional information
Two fully valid oral feed carcinogenesis studies of ascorbic acid were conducted using rats and mice (50 animals per sex and dose in each of the studies). The study period was 103 weeks, the doses were 25,000 and 50,000 ppm in the diet. No adverse effects, neoplastic or non-neoplastic, were seen in either study. Therefore, the maximum ingested dose corresponds to the NOAEL value which was 2,560 and 3,050 mg/kg bw and day in the male and female rat, and 12,788 and 14,792 mg/kg bw and day in the male and female mouse. Ascorbic acid was not carcinogenic in the F344 rat and in the B6C3F1 mouse (NTP, 1983).
This result can be adopted to the corresponding base, the ascorbate anion, and hence to sodium ascorbate. Taking the molecular weights into consideration, this corresponds to 3200 mg/kg bw for the male and 3812 mg/kg bw and day for the female rat.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.